secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001104659-23-086030
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck posts Q2 GAAP loss of $5.98B on $10.2B Prometheus charge; raises FY sales outlook
--------------------------------------------------------------------------------

- GAAP loss per share of $2.35 on net loss of $5,975M; includes $4.02/share charge for Prometheus acquisition.
- Total sales $15,035M (+3% YoY); excluding LAGEVRIO, sales grew 11% (+14% ex-FX).
- KEYTRUDA sales $6,271M (+19% YoY); GARDASIL/GARDASIL 9 sales $2,458M (+47% YoY).
- LAGEVRIO sales fell 83% to $203M; non-GAAP EPS loss of $2.06 vs. $1.87 gain a year ago.
- FY 2023 sales outlook raised to $58.6-59.6B; non-GAAP EPS outlook $2.95-3.05 (includes -$4.53/share one-time charges).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465923086030/0001104659-23-086030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465923086030/tm2322190d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-086030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer